Webinar Recording: Overcoming scFv Instability
Engineering multispecific antibodies often means working with single-chain variable fragments (scFvs). They are elegant in design, but instability, aggregation and poor expression can limit manufacturability and slow down lead selection. In this webinar, experts from AAX Biotech and evitria show how Opti-mAb® technology addresses these risks, and share new data on scFv-containing bi- and trispecific formats.
Watch the full webinar
The recording runs about 40 minutes and shows how Opti-mAb® addresses scFv instability in multispecific formats.
Opti-mAb® and evitria’s expression platform
Opti-mAb® is designed to tackle developability risks at the design and optimization stage, before they become downstream problems. Combined with evitria’s 15 years of experience and our CHO-based transient expression platform, the technology can be applied to design, express and screen a diverse range of molecules.
Working on an scFv-based multispecific?
If your construct aggregates or expresses poorly, we are happy to discuss your project with you.
The Speakers
About evitria
evitria is an established, global antibody engineering and expression service provider located in Zurich, Switzerland specialized in CHO based transient expression of antibodies (including bispecific, multispecific, fusion antibodies) and other proteins. Leveraging long standing expertise, a proprietary CHO-based expression platform and HTP screening, evitria derisks early-stage candidate development in complex formats within the biotech and pharmaceutical industry. evitria AG is part of the Atlas Antibodies group of life science companies, a wholly-owned subsidiary of Patricia Industries.
About Julia Pizzolato PhD
Julia Pizzolato works at the intersection of protein engineering, antibody design, and scientific communication. After completing her PhD at the University of Zurich, she spent 10+ years in biotherapeutics R&D, protein characterization, and analytics for biomanufacturing at several companies in Switzerland. At evitria AG, she supports customers and project teams with technical consultation, feasibility assessments, and training materials, and helps troubleshoot low-expressing or otherwise difficult proteins. She also contributes to internal technology development and process improvements.
About AAX Biotech
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics, based in Stockholm, Sweden. The company offers two unique and proprietary technologies, Seqitope® and Opti mAb®, that enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells.
About Daniel X. Johansson PhD
Daniel X. Johansson is the CEO/CSO and co-founder of AAX Biotech and holds a PhD in Molecular Immunology from Karolinska Institutet, Stockholm, Sweden. He has over 15 years of experience within the field of recombinant antibody technology and engineering in both academia and start-ups. Daniel is the main developer of both AAX technologies, Seqitope® and Opti-mAb®.
Explore more insights and resources to support your antibody development
Discovery panel screening (HTP) & in vivo scale-up
Download our comprehensive case study about HTP screening to see how this method and seamless scale-up accelerate early drug discovery.
Bispecific Antibodies – Webinar
Download the technical webinar recording on high-confidence sequencing and optimized transient CHO expression for bsAb development.
Opti-mAb®: scFv Stabilization
Our technology spotlight on early Opti-mAb® access for scFv stabilization is about addressing instability, aggregation, and poor expression before they limit manufacturability and lead selection.
Fc Engineering: mAb to Bispecific
Get acces to our case study of a tumor-targeting mAb reformatted into a TAA x CD3 bispecific, with six variants delivered in 4.5 weeks and characterized for binding affinity and thermal stability.
GlymaxX®: ADCC Enhancement
In this technology spotlight we explain how GlymaxX® afucosylation enhances ADCC without amino acid substitutions, using ProBioGen cell engineering with transient CHO expression.
Antibody QC by Mass Spectrometry
Download the development guide covering batch-consistent glycan profiles, LC-MS verification of modifications such as afucosylation, and high-throughput mass spectrometry for antibody quality control.
